Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf," cell therapies for serious medical conditions, ...

Lineage Cell Therapeutics (LCTX) announced the receipt of an induced pluripotent stem cell line containing hypoimmunity edits, from Factor ...

New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules SEATTLE--(BUSINESS WIRE)-- As drug ...

The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Sept. 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO for complex biologics and ...

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3 rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2 nd line by early 2026 ...

Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...